menu ☰
menu ˟

FDA grants Lynparza orphan drug designation for pancreatic cancer

16 Oct 2018
The FDA granted orphan drug designation to olaparib for the treatment of patients with pancreatic cancer, according to the agent’s manufacturer.Olaparib (Lynparza, AstraZeneca) is a first-in-class poly ADP-ribose polymerase inhibitor that may explo...

Click here to view the full article which appeared in Gastroenterology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.